Thus, studies have reported that combining receptor tyrosine kinase like orphan receptor 1 (ROR1)-specific CAR T cells with the TGFBR kinase inhibitor SD-208 enhanced clearance of tumors in a mouse model of triple-negative breast cancer [112], whilst CRISPR-mediated deletion of TGFBR2 improved the efficacy of anti-mesothelin CAR-T cells in patient-derived pancreatic cancer xenograft models [113]. This evidence concerns the gene ROR1 and triple-negative breast carcinoma.